Tags

Type your tag names separated by a space and hit enter

Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.
J Am Acad Child Adolesc Psychiatry. 2001 Oct; 40(10):1175-81.JA

Abstract

OBJECTIVE

To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD).

METHOD

Children (6-12 years; n= 72) and adolescents (13-18 years; n = 65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores.

RESULTS

Significant improvement (p < .0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n = 132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61% of adolescents met response criteria (>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p < .05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms.

CONCLUSION

Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.

Authors+Show Affiliations

Department of Psychiatry and Pediatrics, University of Chicago, IL 60637, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11589530

Citation

Cook, E H., et al. "Long-term Sertraline Treatment of Children and Adolescents With Obsessive-compulsive Disorder." Journal of the American Academy of Child and Adolescent Psychiatry, vol. 40, no. 10, 2001, pp. 1175-81.
Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1175-81.
Cook, E. H., Wagner, K. D., March, J. S., Biederman, J., Landau, P., Wolkow, R., & Messig, M. (2001). Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(10), 1175-81.
Cook EH, et al. Long-term Sertraline Treatment of Children and Adolescents With Obsessive-compulsive Disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1175-81. PubMed PMID: 11589530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. AU - Cook,E H, AU - Wagner,K D, AU - March,J S, AU - Biederman,J, AU - Landau,P, AU - Wolkow,R, AU - Messig,M, PY - 2001/10/9/pubmed PY - 2001/11/3/medline PY - 2001/10/9/entrez SP - 1175 EP - 81 JF - Journal of the American Academy of Child and Adolescent Psychiatry JO - J Am Acad Child Adolesc Psychiatry VL - 40 IS - 10 N2 - OBJECTIVE: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). METHOD: Children (6-12 years; n= 72) and adolescents (13-18 years; n = 65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. RESULTS: Significant improvement (p < .0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n = 132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61% of adolescents met response criteria (>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p < .05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms. CONCLUSION: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment. SN - 0890-8567 UR - https://www.unboundmedicine.com/medline/citation/11589530/Long_term_sertraline_treatment_of_children_and_adolescents_with_obsessive_compulsive_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(09)60492-5 DB - PRIME DP - Unbound Medicine ER -